BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36959701)

  • 21. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.
    Peng J; Zuo Z; Fu B; Oki Y; Tang G; Goswami M; Priyanka P; Muzzafar T; Medeiros LJ; Luthra R; Wang SA
    Eur J Haematol; 2016 Jan; 96(1):65-71. PubMed ID: 25809997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
    Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
    Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
    Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
    Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
    Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
    Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
    Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleophosmin mutation analysis in acute myeloid leukaemia: Immunohistochemistry as a surrogate for molecular techniques.
    Chopra A; Soni S; Pati H; Kumar D; Diwedi R; Verma D; Vishwakama G; Bakhshi S; Kumar S; Gogia A; Kumar R
    Indian J Med Res; 2016 Jun; 143(6):763-768. PubMed ID: 27748301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic and genetic characterization of nonacute
    Patel SS; Ho C; Ptashkin RN; Sadigh S; Bagg A; Geyer JT; Xu ML; Prebet T; Mason EF; Seegmiller AC; Morgan EA; Steensma DP; Winer ES; Wong WJ; Hasserjian RP; Weinberg OK
    Blood Adv; 2019 May; 3(9):1540-1545. PubMed ID: 31085507
    [No Abstract]   [Full Text] [Related]  

  • 29. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
    Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
    Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group.
    Cantu MD; Kanagal-Shamanna R; Wang SA; Kadia T; Bueso-Ramos CE; Patel SS; Geyer JT; Tam W; Madanat Y; Li P; George TI; Nichols MM; Rogers HJ; Liu YC; Aggarwal N; Kurzer JH; Maracaja DLV; Hsi ED; Zaiem F; Babu D; Foucar K; Laczko D; Bagg A; Orazi A; Arber DA; Hasserjian RP; Weinberg OK
    JCO Precis Oncol; 2023 Jan; 7():e2200400. PubMed ID: 36689697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of IDH2 Gene Mutation on Clinical Characteristics and Prognostic of Patients with Acute Myeloid Leukemia].
    Luo LQ; Peng ZY; Liu X; Yu WZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1077-1082. PubMed ID: 31418360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
    Falini B
    Am J Hematol; 2023 Sep; 98(9):1452-1464. PubMed ID: 37317978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
    El Hussein S; DiNardo CD; Takahashi K; Khoury JD; Fang H; Furudate K; Lyapichev KA; Garces S; Kanagal-Shamanna R; Ok CY; Patel KP; Routbort MJ; Ravandi F; Medeiros LJ; Wang SA; Loghavi S
    Bone Marrow Transplant; 2022 Mar; 57(3):370-376. PubMed ID: 34992253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
    Konoplev S; Lin P; Yin CC; Lin E; Nogueras González GM; Kantarjian HM; Andreeff M; Medeiros LJ; Konopleva M
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):686-92. PubMed ID: 24035716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
    Dai Q; Ren Y
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A surrogate marker to detect nucleophosnim (NPM1) gene mutations in the cytoplasm of acute myeloid leukemia (AML) blast cells in 30 adult Iraqi patients.
    Al-Husseinawi EK
    Ann Saudi Med; 2013; 33(6):539-46. PubMed ID: 24413856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
    Kansal R
    Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
    Du Pisani LA; Shires K
    Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone Marrow Clonogenic Myeloid Progenitors from
    Guardia RD; González-Silva L; López-Millán B; Rodríguez-Sevilla JJ; Baroni ML; Bueno C; Anguita E; Vives S; Palomo L; Lapillonne H; Varela I; Menendez P
    Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31936647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.